Spots Global Cancer Trial Database for stage iiic melanoma
Every month we try and update this database with for stage iiic melanoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma | NCT00056134 | Melanoma (Skin) | Dendritic cell ... | 18 Years - 120 Years | University Hospital Erlangen | |
| Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib | NCT01519427 | Recurrent Melan... Stage IIIA Mela... Stage IIIB Mela... Stage IIIC Mela... Stage IV Melano... | Akt inhibitor M... selumetinib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Studying Tumor Tissue Samples From Patients With Melanoma Who Have Undergone Sentinel Lymph Node Biopsy | NCT00897481 | Melanoma (Skin) | gene expression... mutation analys... diagnostic labo... immunohistochem... sentinel lymph ... | - | National Cancer Institute (NCI) | |
| Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma | NCT01127451 | Stage IIIC Mela... Stage IV Melano... | Denileukin dift... | 18 Years - | Eisai Inc. | |
| Studying Tumor Tissue Samples From Patients With Melanoma Who Have Undergone Sentinel Lymph Node Biopsy | NCT00897481 | Melanoma (Skin) | gene expression... mutation analys... diagnostic labo... immunohistochem... sentinel lymph ... | - | National Cancer Institute (NCI) | |
| Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma | NCT00003895 | Recurrent Melan... Stage IA Melano... Stage IB Melano... Stage IIA Melan... Stage IIB Melan... Stage IIC Melan... Stage IIIA Mela... Stage IIIB Mela... Stage IIIC Mela... | HPV 16 E7:12-20 gp100:209-217(2... laboratory biom... | 17 Years - | National Cancer Institute (NCI) | |
| Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma | NCT00436605 | Recurrent Melan... Stage IIIA Mela... Stage IIIB Mela... Stage IIIC Mela... Stage IV Melano... | dasatinib | 18 Years - | National Cancer Institute (NCI) | |
| Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | NCT00470470 | Acral Lentigino... Recurrent Melan... Stage IIIA Mela... Stage IIIB Mela... Stage IIIC Mela... Stage IV Melano... | imatinib mesyla... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma | NCT00390338 | Melanoma (Skin) | polarized dendr... non-polarized d... | 18 Years - | University of Pittsburgh | |
| Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery | NCT01748747 | Recurrent Melan... Stage IIA Melan... Stage IIB Melan... Stage IIC Melan... Stage IIIA Mela... Stage IIIB Mela... Stage IIIC Mela... Stage IV Melano... | Montanide ISA 5... MART-1 antigen laboratory biom... Gag:267-274 pep... resiquimod | 18 Years - | Mayo Clinic | |
| Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic | NCT02094872 | Recurrent Melan... Stage IIIA Mela... Stage IIIB Mela... Stage IIIC Mela... Stage IV Melano... | cytology specim... MEK 162 therapy... therapeutic pro... laboratory biom... quality-of-life... | 18 Years - | Yale University | |
| Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma | NCT06190249 | Stage IIIB Mela... Stage IIIC Mela... Stage IIID Mela... | LN-144 Cyclophosphamid... Mesna Fludarabine Interleukin-2 (... Pembrolizumab | 18 Years - | Case Comprehensive Cancer Center | |
| Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma | NCT00390338 | Melanoma (Skin) | polarized dendr... non-polarized d... | 18 Years - | University of Pittsburgh | |
| Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic | NCT02094872 | Recurrent Melan... Stage IIIA Mela... Stage IIIB Mela... Stage IIIC Mela... Stage IV Melano... | cytology specim... MEK 162 therapy... therapeutic pro... laboratory biom... quality-of-life... | 18 Years - | Yale University | |
| Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations | NCT02296112 | Recurrent Melan... Stage IIIB Mela... Stage IIIC Mela... Stage IV Melano... | trametinib laboratory biom... pharmacological... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558 | NCT01176461 | Melanoma (Skin) | MART-1 NY-ESO-1 gp100:209-217(2... gp100:280-288(2... Montanide ISA 5... BMS-936558 | 16 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma | NCT06190249 | Stage IIIB Mela... Stage IIIC Mela... Stage IIID Mela... | LN-144 Cyclophosphamid... Mesna Fludarabine Interleukin-2 (... Pembrolizumab | 18 Years - | Case Comprehensive Cancer Center | |
| Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery | NCT01701037 | Recurrent Melan... Stage IIB Melan... Stage IIC Melan... Stage IIIA Mela... Stage IIIB Mela... Stage IIIC Mela... Stage IV Melano... | dabrafenib trametinib laboratory biom... | 18 Years - 90 Years | Vanderbilt-Ingram Cancer Center | |
| Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or Leg | NCT00565968 | Melanoma (Skin) | melphalan sorafenib tosyl... gene expression... protein express... western blottin... pharmacological... | 18 Years - | Duke University | |
| Studying Tumor Tissue Samples From Patients With Melanoma Who Have Undergone Sentinel Lymph Node Biopsy | NCT00897481 | Melanoma (Skin) | gene expression... mutation analys... diagnostic labo... immunohistochem... sentinel lymph ... | - | National Cancer Institute (NCI) | |
| High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery | NCT02203604 | Recurrent Melan... Stage IIIA Mela... Stage IIIB Mela... Stage IIIC Mela... Stage IV Melano... | aldesleukin ipilimumab laboratory biom... | 18 Years - | Rutgers, The State University of New Jersey | |
| Study of Families With Melanoma | NCT00445783 | Melanoma (Skin) | gene expression... mutation analys... immunohistochem... laboratory biom... examination mutation carrie... study of high r... | 18 Years - | National Cancer Institute (NCI) | |
| Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | NCT00470470 | Acral Lentigino... Recurrent Melan... Stage IIIA Mela... Stage IIIB Mela... Stage IIIC Mela... Stage IV Melano... | imatinib mesyla... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma | NCT00390338 | Melanoma (Skin) | polarized dendr... non-polarized d... | 18 Years - | University of Pittsburgh | |
| Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma | NCT00003895 | Recurrent Melan... Stage IA Melano... Stage IB Melano... Stage IIA Melan... Stage IIB Melan... Stage IIC Melan... Stage IIIA Mela... Stage IIIB Mela... Stage IIIC Mela... | HPV 16 E7:12-20 gp100:209-217(2... laboratory biom... | 17 Years - | National Cancer Institute (NCI) | |
| Identifying Gene Mutations in Patients With Melanoma and in Families With a History of Hereditary Melanoma | NCT00450593 | Hereditary Mult... Melanoma (Skin) | gene expression... microarray anal... molecular genet... mutation analys... laboratory biom... mutation carrie... study of high r... | - | National Cancer Institute (NCI) | |
| Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma | NCT00436605 | Recurrent Melan... Stage IIIA Mela... Stage IIIB Mela... Stage IIIC Mela... Stage IV Melano... | dasatinib | 18 Years - | National Cancer Institute (NCI) | |
| High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery | NCT02203604 | Recurrent Melan... Stage IIIA Mela... Stage IIIB Mela... Stage IIIC Mela... Stage IV Melano... | aldesleukin ipilimumab laboratory biom... | 18 Years - | Rutgers, The State University of New Jersey | |
| Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma | NCT00492505 | Melanoma (Skin) | cisplatin sorafenib tosyl... tamoxifen citra... adjuvant therap... | 18 Years - | National Cancer Institute (NCI) | |
| Biomarkers in Predicting Response to Chemotherapy in Patients With Advanced or Metastatic Melanoma Previously Treated With Carboplatin and Paclitaxel With or Without Sorafenib Tosylate | NCT01209299 | Melanoma (Skin) | DNA methylation... gene expression... laboratory biom... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic | NCT02094872 | Recurrent Melan... Stage IIIA Mela... Stage IIIB Mela... Stage IIIC Mela... Stage IV Melano... | cytology specim... MEK 162 therapy... therapeutic pro... laboratory biom... quality-of-life... | 18 Years - | Yale University | |
| Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma | NCT01176474 | Melanoma (Skin) | NY-ESO-1 157-16... Nivolumab gp100:280-288 (... Montanide ISA 5... Ipilimumab Apheresis Proce... | 16 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma | NCT02507076 | Basal Cell Carc... Eccrine Carcino... Recurrent Adult... Recurrent Melan... Recurrent Skin ... Squamous Cell C... Stage III Adult... Stage IIIB Mela... Stage IIIC Mela... Stage IV Adult ... Stage IV Melano... | isolated limb p... melphalan quality-of-life... | 18 Years - | Albert Einstein College of Medicine | |
| Biomarkers to Predict Response to Interferon Therapy in Patients With Melanoma | NCT00897546 | Melanoma (Skin) | laboratory biom... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery | NCT01835184 | Recurrent Melan... Stage IIIA Mela... Stage IIIB Mela... Stage IIIC Mela... Stage IV Melano... Unspecified Adu... | cabozantinib-s-... vemurafenib laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
